Low-dose interleukin-2 in patients with bipolar depression: A phase 2 randomised double-blind placebo-controlled trial
Brain, Behavior, and Immunity · 2025-01 · 123 · 177-184
DOI: 10.1016/j.bbi.2024.09.005 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Brain, Behavior, and Immunity, 2025-01. Verfasst von Marion Leboyer und 12 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Est Créteil (UPEC), AP-HP, Department of Psychiatry, Hôpital Henri Mondor, DMU IMPACT, FHU ADAPT, INSERM U955, IMRB, Translational N…. Hauptthemen laut MEDLINE: Bipolar Disorder, Interleukin-2, T-Lymphocytes, Regulatory. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Assistance Publique - Hôpitaux de Paris, European Commission, Horizon 2020 Framework Programme.
Themen: Depression
Abstract (Originalsprache)
Immune abnormalities including an insufficiency of regulatory T cells (Treg) and increased blood-based inflammatory markers have been observed in bipolar disorders (BD), particularly during depression. As Tregs are pivotal to control inflammation, Treg stimulation by low-dose IL-2 (IL-2LD) could have a therapeutic impact on bipolar depression. We performed a randomized, double-blind, placebo-controlled (2 active: 1 placebo) proof-of-concept trial of add-on IL-2LD in patients with bipolar depression. Patients received a placebo or IL-2LD (1MIU) once a day for 5 days, and then once a week for 4 weeks starting on week 2. The primary objective was to demonstrate a biological Treg response to IL-2LD assessed by fold increase in Treg percentage of CD4 + cells from baseline to day 5. Secondary objectives included safety assessment and mood improvement throughout the study period. This trial is registered with ClinicalTrials.gov, number NCT04133233. Fourteen patients with bipolar depression were included, with 4 receiving placebo and 10 IL-2LD. Baseline clinical and biological characteristics were balanced between groups. The primary evaluation criterion was met, with IL-2LD expanding 1.17 [95 % CI 1.01-1.34] vs 1.01 [95 % CI 0.90-1.12] (p = 0.0421) and activating Tregs. Secondary evaluation criteria were also met with significant improvements of depressive symptoms and global functioning from day-15 onwards in the IL-2LD treated patients. The treatment was well-tolerated, with no serious adverse events related to treatment. This proof-of-concept trial shows that stimulating Tregs in patients with bipolar depression is safe and associated with clinical improvements. This supports a pathophysiological role of inflammation in BD and warrants pursuing the evaluation of IL-2LD as an adjunct treatment of major mood disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université Paris Est Créteil (UPEC), AP-HP, Department of Psychiatry, Hôpital Henri Mondor, DMU IMPACT, FHU ADAPT, INSERM U955, IMRB, Translational NeuroPsychiatry Laboratory, 51 Avenue du Maréchal de Lattre de Tassigny…
- Sorbonne Université, INSERM, UMR_S 959, Immunology-Immunopathology- Immunotherapy (i3), F-75651 Paris, France.
- Sorbonne Université, INSERM, UMR_S 959, Immunology-Immunopathology- Immunotherapy (i3), F-75651 Paris, France; AP-HP, Pitié-Salpêtrière Hospital, Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Departme…
- Inserm, Centre d'Investigation Clinique 1430 et AP-HP, Hôpitaux Universitaires Henri Mondor, Univ Paris Est Creteil, F-94010 Créteil, France.
- AP-HP, Saint Louis/Lariboisière Hospitals, Unité de recherche clinique and Université Paris 7, F-75010 Paris, France.
Förderung
- Assistance Publique - Hôpitaux de Paris
- European Commission
- Horizon 2020 Framework Programme
- Agence Nationale de la Recherche
Zitieren
APA
Leboyer, M., Foiselle, M., Tchitchek, N., Tamouza, R., Lorenzon, R., Richard, J. R., Arrouasse, R., Le Corvoisier, P., Le Dudal, K., Vicaut, E., Ellul, P., Rosenzwajg, M., & Klatzmann, D. (2025). Low-dose interleukin-2 in patients with bipolar depression: A phase 2 randomised double-blind placebo-controlled trial. Brain, Behavior, and Immunity, 123, 177-184. https://doi.org/10.1016/j.bbi.2024.09.005
Vancouver
Leboyer M, Foiselle M, Tchitchek N, Tamouza R, Lorenzon R, Richard JR, et al. Low-dose interleukin-2 in patients with bipolar depression: A phase 2 randomised double-blind placebo-controlled trial. Brain, Behavior, and Immunity. 2025;123:177-184. doi:10.1016/j.bbi.2024.09.005
BibTeX
@article{Leboyer2025,
author = {Leboyer, Marion and Foiselle, Marianne and Tchitchek, Nicolas and Tamouza, Ryad and Lorenzon, Roberta and Richard, Jean-Romain and Arrouasse, Raphaele and Le Corvoisier, Philippe and Le Dudal, Katia and Vicaut, Eric and Ellul, Pierre and Rosenzwajg, Michelle and Klatzmann, David},
title = {Low-dose interleukin-2 in patients with bipolar depression: A phase 2 randomised double-blind placebo-controlled trial},
journal = {Brain, Behavior, and Immunity},
year = {2025},
volume = {123},
pages = {177--184},
doi = {10.1016/j.bbi.2024.09.005}
}
EUVIMED